Cargando…

Severe Pulmonary Toxicity With Concurrent Anlotinib and Chemoradiotherapy in Stage III NSCLC: The ALTER-L042 Phase 1 Clinical Trial

INTRODUCTION: Anlotinib has brought about marked progression-free survival and overall survival benefit compared with placebos as third-line or further treatment in advanced NSCLC. Nevertheless, the safety and efficacy of concurrent anlotinib and chemoradiotherapy are still unclear. METHODS: Patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Hui, Jia, Wenxiao, Jing, Xuquan, Huang, Wei, Wang, Linlin, Yu, Jinming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160472/ https://www.ncbi.nlm.nih.gov/pubmed/35663415 http://dx.doi.org/10.1016/j.jtocrr.2022.100339

Ejemplares similares

Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC
por: Kuge, Tomoki, et al.
Publicado: (2023)

Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy
por: Lau, Sally C.M., et al.
Publicado: (2021)

Pretreatment SUV(max) value to predict outcome in patients with stage III NSCLC receiving concurrent chemoradiotherapy
por: Yaprak, Gokhan, et al.
Publicado: (2019)

IDO1 Activity Predicts Lung Toxicity in Patients with Unresectable Stage III NSCLC and Chemoradiotherapy
por: Wu, Linfang, et al.
Publicado: (2023)

Concurrent chemoradiotherapy plus anlotinib vs. concurrent chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma: An interim analysis of a multicenter randomized controlled trial
por: Chen, Kequan, et al.
Publicado: (2023)

Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab
por: Guggenberger, J., et al.
Publicado: (2022)

Comparative Clinical Efficacy of ‘Concurrent Chemoradiotherapy (CCRT) and Anlotinib’ Than CCRT in Patients with Locally Advanced ESCC
por: Wang, Gang, et al.
Publicado: (2022)

Tracheo-parenchymal fistula following concurrent chemo-radiation for stage III NSCLC
por: Alzghoul, Bashar, et al.
Publicado: (2016)

The addition of anlotinib reduces the incidence of radiation and immunotherapy-induced pneumonia
por: Yang, Linlin, et al.
Publicado: (2023)

Concurrent chemoradiotherapy for elderly patients with stage III non-small cell lung cancer
por: Kang, Ki Mun, et al.
Publicado: (2012)

Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer
por: Conibear, John
Publicado: (2020)

High-dose concurrent chemo–proton therapy for Stage III NSCLC: preliminary results of a Phase II study
por: Oshiro, Yoshiko, et al.
Publicado: (2014)

Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC
por: Shaverdian, Narek, et al.
Publicado: (2021)

Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604)
por: Tahara, Makoto, et al.
Publicado: (2015)

Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Patients With Stage IIB-IVA Cervical Cancer: A Randomized Phase III Trial
por: He, Shasha, et al.
Publicado: (2022)

Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)—a German radiation oncology survey
por: Käsmann, Lukas, et al.
Publicado: (2020)

Concurrent chemoradiotherapy versus radiotherapy alone after induction chemoimmunotherapy for stage III NSCLC patients who did not undergo surgery: a single institution retrospective study
por: Guan, Song, et al.
Publicado: (2023)

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
por: Gray, Jhanelle E., et al.
Publicado: (2019)

Pathological response to neoadjuvant therapy with chemotherapy vs chemoradiotherapy in stage III NSCLC-contribution of IASLC recommendations
por: Muñoz-Guglielmetti, Diego, et al.
Publicado: (2021)

Dynamic change of IDO1 activity predicts survival in patients with unresectable stage III NSCLC and chemoradiotherapy
por: Wu, Linfang, et al.
Publicado: (2022)

Predictive value of microvascular density for response to anlotinib in advanced NSCLC
por: Liu, Danqing, et al.
Publicado: (2022)

Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC
por: Jing, Wang, et al.
Publicado: (2022)

Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysis
por: Flörsch, Benedikt, et al.
Publicado: (2022)

Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer
por: Abacioglu, Ufuk, et al.
Publicado: (2005)

Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition
por: Unterrainer, Marcus, et al.
Publicado: (2021)

Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction
por: Zhao, Qun, et al.
Publicado: (2015)

Efficacy of concurrent chemoradiotherapy in subgroups of stage III nasopharyngeal carcinoma: an analysis based on 10-year follow-up
por: Wang, Lei, et al.
Publicado: (2021)

Early recurrence factors in patients with stage III non‐small cell lung cancer treated with concurrent chemoradiotherapy
por: Takahara, Yutaka, et al.
Publicado: (2022)

Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study)
por: Yamada, Tadaaki, et al.
Publicado: (2020)

A phase III randomized, controlled trial of nedaplatin versus cisplatin concurrent chemoradiotherapy in patients with cervical cancer
por: Yang, X., et al.
Publicado: (2022)

GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy
por: Zhou, Qing, et al.
Publicado: (2020)

Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study
por: Guo, Shan-Shan, et al.
Publicado: (2016)

Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Trospective Comparison Focusing on Pulmonary Toxicity
por: Wass, Romana, et al.
Publicado: (2022)

Report, CERN-SPSC-89-042
por: CERN. Geneva. SPS Experiments Committee
Publicado: (1989)

Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer
por: Huang, Yiqing, et al.
Publicado: (2022)

Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study
por: Tang, Shi, et al.
Publicado: (2023)

Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer
por: Hu, Nanlin, et al.
Publicado: (2021)

Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma
por: Shi, Jingzhen, et al.
Publicado: (2020)

Addition of Induction or Consolidation Chemotherapy in Definitive Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone for Patients With Unresectable Esophageal Cancer: A Systematic Review and Meta-Analysis
por: Wang, Jianing, et al.
Publicado: (2021)

Randomized phase III trial of concurrent chemoradiotherapy vs accelerated hyperfractionation radiotherapy in locally advanced head and neck cancer
por: Chitapanarux, Imjai, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_31gn8q1oln1ri8v5te28nchpae